ClinicalTrials.gg
Not yet recruitingNCT07938619Updated Nov 16, 2026

Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Tafasitamab and Lenalidomide in Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Sun Yat-sen University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
10th of 11
29 · median 39
Started
2026
with 1 other
Phase 2
8 of 11
6 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
Sun Yat-sen University

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 2, and was the 11th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

03

Conditions studied

  • Diffuse Large B Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to participate in the clinical study and signed .
  2. Age ≥18 years, no gender restrictions.
  3. confirmed diffuse large B-cell lymphoma; ineligible for or unable to access stem cell transplantation (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy.
  4. Has at least one measurable or assessable lesion.
  5. performance status (ECOG PS) score ≤
  6. Adequate major organ function.

Exclusion criteria

Exclusion Criteria:

  1. DLBCL with central nervous system involvement or Burkitt lymphoma.
  2. Disease progression following prior frontline treatment with a Bruton tyrosine kinase inhibitor (BTKi).
  3. Active (HIV) or virus (HCV) infection.
  4. Inability to swallow capsules or significant gastrointestinal impairment that may affect drug absorption.
  5. Other progressive requiring active treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    Tafasitamab in combination with Lenalidomide, Rituximab and Orelabrutinib

    Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.

    Drug: Tafasitamab · Drug: Lenalidomide · Drug: Rituximab · Drug: Orelabrutinib

Interventions

  • 12mg/kg, IV, C1-3: D1, 8, 15, 22 (with an additional loading dose on C1D4), C4-12: D1, 15.

  • 25mg, PO, day 1-21 of cycle 1-12

  • 375mg/m2, IV, day 1 of cycle 1-4

  • 150mg or 100mg, PO, day 1-28 of cycle 1-4

06

What researchers measure

Primary outcomes

  1. Complete response rate (CRR)

    CRR was defined as the proportion of patients who achieve complete response (CR)

    Time frame: Up to 12 cycles ( each cycle is 28 days)

Secondary outcomes

  1. Objective response rate (ORR)

    ORR was defined as the proportion of patients who achieve complete response (CR) or partial response (PR)

    Time frame: Up to 12 cycles (each cycle is 28 days)

  2. Disease control rate (DCR)

    DCR was defined as the proportion of patients who achieve complete response (CR), partial response (PR) and stable disease (SD)

    Time frame: Up to 12 cycles (each cycle is 28 days)

  3. Duration of Response (DoR)

    DoR was defined as the time from the patients's first efficacy assessment achieving CR or PR until disease progression

    Time frame: up to 3 years

  4. Duration of Complete Response (DoCR)

    DoCR was defined as the time from the patients's first efficacy assessment achieving CR until disease progression

    Time frame: up to 3 years

  5. Progression-free survival (PFS)

    PFS was defined as the time from the date of the first administration of any study drug to the date of tumor progression or death from any cause

    Time frame: up to 3 years

  6. Overall survival (OS)

    OS was defined as the time from the date of the first administration of any study drug until death from any cause

    Time frame: up to 3 years

  7. Time to Response (TTR)

    TTR was defined as the time from the initiation of treatment to the patients's first efficacy assessment achieving CR or PR

    Time frame: Up to 12 cycles (each cycle is 28 days)

  8. Adverse events

    The incidence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    Time frame: Up to 28 days after the last dose of study drug

  9. Change in Quality of Life

    Quality of life will be assessed using the EORTC QLQ-C30 questionnaire

    Time frame: Up to 3 years

07

Study locations

3 sites
  • Sun Yat-sen Univercity Cancer Center, Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
  • The Fifth Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
    • Runhui Zheng · Contact
  • The Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
    • Ning Su · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 24 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938619
Responsible party
Qingqing Cai (Principal Investigator, Sun Yat-sen University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Qingqing Cai
Contact
caiqq@sysucc.org.cn
020-87342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion